Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma implications for optimal clinical testing

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 7, 2012, Pages 796-803

  Wallander, Michelle L ^a   Geiersbach, Katherine B ^a   Tripp, Sheryl R ^b   Layfield, Lester J ^b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CELL CYCLE PROTEIN; EML4 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; SERINE PROTEINASE;

ARTICLE; COMPARATIVE STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; METHODOLOGY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; ONCOGENE PROTEINS, FUSION; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SERINE ENDOPEPTIDASES;

EID: 84864231379     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0321-OA     Document Type: Article

References (27)

1. Pao W, Chmielecki J. Rational, biologically based treatment of EGFRmutant non-small cell lung cancer. Nat Rev Cancer. 2010;10(11):760-774.
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature. 2007;448(7153): 561-566. (Pubitemid 47206930)
3. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008; 68(13):4971-4976.
4. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14(20):6618- 6624.
5. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15(9):3143-3149.
6. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13): 4275-4283.
7. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723-1733.
8. Sanders HR, Li HR, Bruey JM, et al. Exon scanning by reverse transcriptasepolymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet. 2011;204(1):45-52.
9. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK- positive lung cancer. Proc Natl Acad Sci U S A. 2008;105(50):19893-19897.
10. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
11. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247-4253.
12. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010; 16(22):5581-5590.
13. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010;9:188.
14. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216-5223.
15. Yoshida A, Tsuta K, Kohno T, et al. Most ALK-positive lung adenocarcinomas exhibit characteristic histology [abstract]. Mod Pathol. 2011;24(suppl 1s): 429A.
16. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3(1): 13-17.
17. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 2009;4(12):1450-1454.
18. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small cell lung cancer. J Clin Oncol. 2009;27(26):4232-4235.
19. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008;68(9):3389-3395.
20. Layfield LJ, Willmore C, Tripp S, Jones C, Jensen RL. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl Immunohistochem Mol Morphol. 2006;14(1):91-96.
21. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009; 174(2):661-670.
22. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009;40(8):1152-1158.
23. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010; 17(3):889-897.
24. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16(5):1561-1571.
25. Saab ST LC, Hollis CJ, Ashwini Y, Ji H, Pao W, Gonzalez A. Immunohistochemical analysis of ALK fusion-positive lung cancers: correlation with FISH, molecular findings and morphology [abstract 1799]. Mod Pathol. 2011;24(suppl 1s):423A.
26. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008;10(3):298-302. (Pubitemid 351328588)
27. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009;7(9): 1466-1476.